Curevac appoints thaminda ramanayake as new chief business officer

Mr. ramanayake brings more than fifteen years of experience in biopharma company development and deal-making strong track record of successful clinical collaborations, m&a, asset in-licensing and strategic financing initiatives across multiple therapeutic areas tÜbingen, germany and boston, ma / accesswire / april 24, 2024 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced that thaminda ramanayake has been appointed to the role of chief business officer, effective june 1, 2024.
CVAC Ratings Summary
CVAC Quant Ranking